-
Qilu enters the market with annual sales of $1.9 billion blockbuster drug and Chengdu Beite competes for the first imitation
Time of Update: 2021-06-17
Figure 1: The status of products declared by Qilu Pharmaceutical Figure 2: Gilead’s global sales of emtricitabine and propofol tenofovir (unit: million dollars) Source: Mynet.
-
Puli Pharmaceuticals successfully won the best-selling anticoagulant ANDA in a patent challenge
Time of Update: 2021-06-08
to sell bivalridine for injection in the United States. Table 2: The ANDA document numbers that Puli Pharmaceutical has obtained earlier Source
-
Yiling Pharmaceutical won the "2021 China Brand (Industry) Top Ten Innovative Enterprises"
Time of Update: 2021-06-04
Medical Network News, June 1st, May 27th, by the "China Enterprise News" group, the special issue department of the Consumer Daily, the "Discover Brand" column group, the online
-
Shandong pharmaceutical companies show their power!
Time of Update: 2021-06-01
Recently, Shandong New Times Pharmaceuticals has approved three more varieties, including axitinib tablets, lipoic acid injection, and tenofovir fumarate.
-
To Biao Hengrui and Sanofi!
Time of Update: 2021-05-22
Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
-
Chia Tai Tianqing approved the third high-end generic drug this year, pointing to Merck's heavy variety
Time of Update: 2021-05-21
Pharmanet News, May 14 Recently, Chia Tai Tianqing Pharmaceutical Group's application for the imitation of Aprepitant Capsule 4 was approved, becoming the second domestic pharmaceutical company to be approved for the product and deemed to have been reviewed.
-
Pfizer acquires Amplyx to expand anti-infective drug R&D pipeline
Time of Update: 2021-05-10
In addition to fosmanogepix, through this acquisition, Pfizer also acquired the ownership of Amplyx's early-stage pipeline, which includes potential antiviral (MAU868) and antifungal (APX2039) therapies.
-
Cinda ophthalmic drug IBI302 Phase II clinical completed the first patient administration
Time of Update: 2021-05-10
In the ongoing phase II clinical study, in addition to evaluating the efficacy of IBI302 in improving vision and retinal thickness, it will also focus on its potential improvement effect on macular atrophy and fibrosis.
-
The reasons for the suspension of Roche's tominersen phase III trial were repeated, and analysts put forward four hypotheses
Time of Update: 2021-05-10
Roche said that after the independent data committee "has questioned the benefits and safety risks of subjects receiving tominersen therapy," Roche decided to stop late-stage clinical trials of the antisense drug tominersen for huntingtin and mutants.
-
Roche's innovative anti-influenza drug Sufuda® was officially approved in China
Time of Update: 2021-05-10
, timely and targeted antiviral treatment should be given.
>
Mabaloxavir is an innovative cap-shaped structure-dependent endonuclease inhibitor. A single oral administration of mabaloxavir
-
Johnson & Johnson CD38 monoclonal antibody new indication approved in China, sales of 4.19 billion U.S. dollars in 2020
Time of Update: 2021-05-10
Although many progresses have been made in the treatment of multiple myeloma in recent years, most patients still face the problem of relapse or drug resistance.
-
Improved new drug "Budesonide Sustained Release Capsules" receives FDA priority review for the treatment of IgA nephropathy
Time of Update: 2021-05-10
On April 28, Calliditas announced that its new drug application (NDA) for Nefecon (Budesonide Sustained Release Capsules) has been accepted by the FDA for the treatment of IgA nephropathy.
-
Roche's flu drug "Mabaloxavir" approved for listing in China
Time of Update: 2021-05-10
The results of the study showed that the median flu symptom improvement time (TTIIS) of patients in the mabaloxavir group was shorter than that of the oseltamivir group and placebo group, which were 73.
-
Chengdu Xiandao HG146 Capsule New Indication Clinical Trial Application Approved
Time of Update: 2021-05-10
>
Recently, Chengdu Pilot issued an announcement stating that the company has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products
-
6 best-selling anti-tumor varieties can be used by children in Hengrui, Hausen, and Yangtze River...the product has exploded
Time of Update: 2021-05-10
According to data from Meinenet, the above-mentioned 6 anti-tumor drugs are all varieties of the 2020 National Medical Insurance Catalogue, and domestic giants such as Hengrui, Qilu, Shuanglu Pharmaceutical, Baiyunshan, and Yangzijiang have layouts.
-
Osaicam posaconazole injection is about to pass the consistency evaluation
Time of Update: 2021-05-10
Recently, NMPA official website data shows that Osaikon’s posaconazole injection 3 types of imitation listing applications have entered the "under review" status, and it is expected to win the first domestic imitation + first review.
-
GSK's first-quarter results failed to meet expectations and will reduce more anti-cancer drug inputs
Time of Update: 2021-05-10
about 10. 3 billion U. S. dollars (7. 4 billion pounds). At a constant exchange rate, it was 15% lower than the first quarter of last year, which was lower than analysts. Projected 7. 88
-
Hengrui PD-1 nasopharyngeal carcinoma indication approved
Time of Update: 2021-05-10
The approved indication is: for the treatment of advanced nasopharyngeal carcinoma patients who have previously received second-line or above chemotherapy and have advanced or intolerable disease.
-
Novo Nordisk's "once a week" new diabetes drug is officially approved in China
Time of Update: 2021-05-10
On April 29, Novo Nordisk issued a press release stating that the National Medical Products Administration (NMPA) has approved Novo Nordisk's research and development and production of Novotel® (Smeglutide Injection) in China for the listing application.
-
A well-known pharmaceutical company of RMB 487.5 million was acquired to deploy innovative drug research and development
Time of Update: 2021-05-08
5 million yuan, a well-known pharmaceutical company was acquired Well-known pharmaceutical company was acquired Huadong Medicine announced the acquisition of a 75% stake in Zhejiang Daoer Biotechnology Co.
